Results 11 to 20 of about 1,982,916 (349)

Ductal carcinoma in situ: to treat or not to treat, that is the question

British Journal of Cancer, 2019
Ductal carcinoma in situ (DCIS) now represents 20–25% of all ‘breast cancers’ consequent upon detection by population-based breast cancer screening programmes.
M. Seijen, E. Lips, A. Thompson, S. Nik-Zainal, A. Futreal, E. Hwang, E. Verschuur, J. Lane, J. Jonkers, D. Rea, J. Wesseling, J. Wesseling, Precision team   +12 more
semanticscholar   +1 more source

Profile of Digital Mammography Findings in Patients with Histopathologically Proven Ductal Carcinoma in Situ (DCIS)

Galician Medical Journal, 2020
Breast carcinoma is a heterogeneous group of tumors with a wide spectrum of clinical presentations, lesion characterization and diagnostic evaluation.
Ankit Prabhakar, Dawood Iqbal Wani, Shivani Sharma, Sajjad Ahmad Dar, Shaafiya Ashraf   +4 more
doaj   +1 more source

An Unusual Presentation of Extensive Ductal Carcinoma in Situ Accompanying Invasive Ductal Carcinoma on MRI: A Case Report

대한영상의학회지, 2022
The incidence of ductal carcinoma in situ has increased with the rise in screening mammography; currently, ductal carcinoma in situ constitutes 20%–25% of all breast cancers, and up to half of them may become invasive.
Yeon Jung Kim, Hyun Kyung Jung, Woogyeong Kim
doaj   +1 more source

The Role of Elastography in Predicting the Grade of Mammary Ductal Carcinoma

The Iraqi Journal of Medical Sciences, 2022
Background: Elastography is an imaging technique which has been used in the last decades and its role in breast masses characterization is well established. However, its value for predicting breast cancer grading is yet to be studied. Objective:
Taimaa T.M. Said, Alaa Sheet, Bilal Nuaman   +2 more
doaj   +1 more source

Contralateral prophylactic mastectomies. Correlations between primary tumor and histological findings of controlateral breast [PDF]

, 2016
Backgound: In Italy in 2015 48,000 new cases of breast carcinomas were diagnosed. Women who are diagnosed with breast cancer have a significant risk of developing contralateral breast cancer during the rest of their lives and this risk is closely ...
Amanti, Claudio, Argento, Giuseppe, Campanella, L, Cunsolo, G, DI STEFANO, Domenica, Lombardi, Augusto, Maggi, Stefano, Mastrangeli, Mr, Mattei, Ms, Stanzani, G, Vitale, Valeria   +10 more
core   +1 more source

Ductal carcinoma in situ of breast: update 2019.

Pathology (Sydney), 2019
Ductal carcinoma in situ is a non-invasive form of breast cancer. Its incidence is increasing due to widespread use of mammographic screening. It presents several diagnostic and management challenges in part due to its relatively indolent behaviour. Most
S. Badve, Yesim Gökmen‐Polar
semanticscholar   +1 more source

Potential biomarkers of ductal carcinoma in situ progression

BMC Cancer, 2020
Background Ductal carcinoma in situ is a non-obligate precursor of invasive breast carcinoma and presents a potential risk of over or undertreatment. Finding molecular biomarkers of disease progression could allow for more adequate patient treatment.
Raquel Spinassé Dettogni, Elaine Stur, Ana Carolina Laus, René Aloísio da Costa Vieira, Márcia Maria Chiquitelli Marques, Iara Viana Vidigal Santana, José Zago Pulido, Laura Fregonassi Ribeiro, Narelle de Jesus Parmanhani, Lidiane Pignaton Agostini, Raquel Silva dos Reis, Eldamária de Vargas Wolfgramm dos Santos, Lyvia Neves Rebello Alves, Fernanda Mariano Garcia, Jéssica Aflávio Santos, Diego do Prado Ventorim, Rui Manuel Reis, Iúri Drumond Louro   +17 more
doaj   +1 more source

Using of Binominal Method for the Purpose of Determination of Confidence Intervals for Prediction of Invasive Ductal Breast Carcinoma Metastases [PDF]

, 2016
The study was performed using surgical and biopsy material based on histopathological study, which was conducted at the Chernivtsy Regional Clinical Oncology Centre.
Davydenko, I. (Igor), Lazaruk, A. (Alexandr)   +1 more
core   +2 more sources

Evaluation of a Novel Anti-Mucin 1 (MUC1) Antibody (PankoMab) as a Potential Diagnostic Tool in Human Ductal Breast Cancer; Comparison with Two Established Antibodies [PDF]

, 2009
Aim: PankoMab is a novel antibody that recognizes a tumor-specific epitope of Mucin 1 (MUC1). The aim of this study was the evaluation of PankoMab as a potential diagnostic tool and its comparison with two established antibodies against MUC1 in human ...
Dian, Darius, Friese, Klaus, Janni, Wolfgang, Jeschke, Udo, Karsten, Uwe, Kuhn, Christina, Mayr, Doris, Mylonas, Ioannis   +7 more
core   +1 more source

Breast Ductal Carcinoma In Situ [PDF]

International Journal of Surgical Oncology, 2012
Ductal carcinoma in situ (DCIS) of the breast is becoming one of the most important diseases diagnosed in preventive medicine screening. The current age-adjusted incidence rate of DCIS is 32.5 per 100,000 women. For women 50–64 years of age, the incidence is approximately 88 per 100,000. Currently, for every 4 diagnoses of invasive breast cancer, there
V. Sacchini, L. Fortunato, H. S. Cody Iii, K. J. Van Zee, B. Cutuli, B. Bonanni   +5 more
openaire   +2 more sources